Ad-ISF35 is an adenovirus (Ad) vector that encodes a mouse --human chimeric CD154. Ad-ISF35 induces activation of chronic lymphocytic leukemia (CLL) cells converting them into CLL cells capable of promoting immune recognition and anti-leukemia T-cell activation. Clinical trials in humans treated with Ad-ISF35-transduced leukemia cells or intranodal injection of Ad-ISF35 have shown objective clinical responses. To better understand the biology of Ad-ISF35 and to contribute to its clinical development, we preformed studies to evaluate biodistribution, persistence and toxicity of repeat dose intratumoral administration of Ad-ISF35 in a mouse model. Ad-ISF35 intratumoral administration induced tumor regression in more than 80% of mice bearing A20 tumors. There were no abnormalities in the serum chemistry. Mice receiving Ad-ISF35 presented severe extramedullary hematopoiesis and follicular hyperplasia in the spleen and extramedullary hematopoiesis with lymphoid hyperplasia in lymph nodes. After Ad-ISF35 injection, the vector was found primarily in the injected tumors with a biodistribution pattern that showed a rapid clearance with no evidence of Ad-ISF35 accumulation or persistence in the injected tumor or peripheral organs. Furthermore, pre-existing antibodies against Ad-5 did not abrogate Ad-ISF35 anti-tumor activity.
INTRODUCTION CD40L, also known as CD154, is the main ligand for CD40. Signaling via CD40 activates antigen-presenting cells both in vitro and in vivo.
1 --3 CD40 ligation on dendritic cells induces cellular maturation and activation as detected by increased surface expression of co-stimulatory and major histocompatibility complex molecules, production of proinflammatory cytokines, such as interleukin 12, and enhanced T-cell activation.
1 CD40 ligation of resting B cells increases antigen-presenting function and induces proliferation and immunoglobulin class switching. 4 After CD154 stimulation, leukemia B cells become effective antigen-presenting cells and induce T-cell activation and cytotoxicity against leukemia cells. These effects are mediated by upregulation of co-stimulatory molecules (CD54, CD70, CD80 and CD86) and death receptors (CD95, DR5). 5, 6 Moreover, CD40/CD154 interaction may be a critical signaling component in the tumor microenvironment. It has been reported that the microenvironment can protect cancer cells from apoptosis and confer resistance to chemotherapy. 7 --9 These protected cancer cells can be the source of circulating tumor cells as well as metastatic tumor spread, 10 and failure of current cancer treatments may be due, at least in part, to lack of activity in 'highly protected' niches of residual tumor cells embedded in the microenvironment. Recent data highlight the relevance of CD40-mediated immune activation of cells present in the microenvironment, specifically macrophages in which CD40 signaling can promote direct cytotoxicity that contributes to effective tumor surveillance. 11 Interestingly, almost 100% of B-cell malignancies and up to 70% of solid tumors express CD40 and signaling through this pathway can result not only in cell activation, but also in apoptosis of cancer cells. 12, 13 Therefore, CD40/CD154 signaling can been considered a therapeutic target with applications not only in B-cell malignancy, but also in solid tumors.
Studies conducted with anti-CD40 antibodies or recombinant human CD40 ligand have reported objective clinical activity in patients with solid tumors, chronic lymphocytic leukemia (CLL) and lymphomas. 11, 14, 15 In addition, our previous studies using adenovirus (Ad) vectors that encode mouse CD154 provide proof of principle showing that CD40/CD154-mediated immunotherapy is feasible and effective in cancer patients. 15, 16 However, patients who received autologous cells transduced to express mouse CD154 developed antibodies against it. Therefore, we have developed Ad-ISF35, which expresses a novel chimeric human --mouse CD40 binding protein that does not contain the antibody binding mouse domains targeted by human neutralizing antibodies (Nabs). ISF35 protein also resists cleavage, maximizing cell surface expression.
We have studied the safety of a single intratumoral injection of Ad-ISF35 in patients with chronic lymphocytic leukemia (CLL) (paper under review). In these studies, we have observed objective clinical responses with patients showing decreased leukemia cell counts as well as lymph node and spleen size reductions. Adverse events have been transient and mild, including 'flu-like' symptoms, hypophosphatemia and neutropenia.
On the basis of the encouraging results using a single Ad-ISF35 intranodal injection, we hypothesize that repeat dose administration will result in a greater clinical benefit. Therefore, we performed several studies to understand better the biology of Ad-ISF35 and to evaluate its safety, vector biodistribution, persistence and transgene expression after repeat dose intratumoral administration in a lymphoma mouse model using A20 cells implanted in BALB/c mice.
MATERIALS AND METHODS

Adenoviral vector
GMP quality Ad-ISF35 was provided by Memgen LLC (San Diego, CA) under licensing from University of California, San Diego (UCSD San Diego, CA). Ad-ISF35 was handled, purified and tested following GMP standards that satisfy Food and Drug Administration (FDA) requirements for clinical use in human patients. The vector was produced in 293 cells, which contained the E1 region of the viral genome to complement the deletion of that region from the vector itself. This deletion renders the vector incapable of replication outside the packaging cell line. We determined viral particles (vp per ml (mass spectrometry), infectious units (IU) per ml (Adeno-X rapid titer; Clontech, Mountain View, CA), presence of the ISF35 transgene (quantitative polymerase chain reaction (qPCR)), absence of endotoxins and replication-competent Ad, and sterility. This lot of vector passed all tests and each ml of Ad-ISF35 vector contained 4.46 Â 10 11 vp (7.69 Â 10 10 IU per ml). Recombinant Ad vector serotype 5 lacking the transgene was used as a control. Its production was performed using 293 cells and purified by cesium chloride gradients. Viral infection units were measured using Adeno-X rapid titer kit (Clontech) following the manufacturer's instructions.
Animal inoculation
In all, 35 male and 35 female BALB/c mice, 6 --7 weeks of age were obtained from Harlan Sprague --Dawley (Indianapolis, IN). Explora Biolabs (San Diego, CA) performed in vivo animal studies. Biological samples were processed and tested at UCSD according to the biosafety guidelines and protocols from UCSD and in compliance with FDA guidelines. 17 All animals were allowed to acclimate to the housing environment before implanting tumor cells. Animals were injected subcutaneously with 1 Â 10 5 A20 cells (B-cell lymphoma cell line), in the right flank region. When average tumor size reached approximately 125 --200 mm 3 , the animals were randomly divided into the groups (five males and five females per group) described in Table 1 to assure proper distribution of tumor size among the different groups. The animals were divided into groups and received single or repeat (three injections) administration of vehicle (Tris-lactose NaCl), 3 Â 10 9 or 3 Â 10 10 vp of Ad-ISF35. Day 0 was defined as the day when mice received the first injection of vehicle or Ad-ISF35. Mice injected once were killed 5 days after Ad-ISF35 injection. The mice receiving repeat administration were killed 5 days after the last injection (19 days after the first injection). A separate group of animals receiving repeat administration of Ad-ISF35 (3 Â 10 10 vp) was followed up for 25 days (after the last injection) to evaluate for delayed toxicities.
Tumor size measurements
Tumor length and width were measured using a caliper. Tumor volumes were calculated by (length Â width 2 )/2. If a second tumor occurred in a given mouse, both tumor volumes were measured and their volumes were added together.
Analysis of vector biodistribution
Vector biodistribution was analyzed in different organs and time points. First, we measured vector biodistribution after single administration of Ad-ISF35 (3 Â 10 10 vp) at 2, 6, 24, 48 and 120 h after injection. Second, we compared vector biodistribution at 120 h after single or repeat administration of Ad-ISF35. Third, we evaluated the effect of Nabs in mice preimmunized with Ad-5 and Ad-ISF35 in vector biodistribution 2 h following a single Ad-ISF35 intratumoral administration. In all, 10 organs from each mouse (brain, lungs, heart, spleen, liver, kidney, small intestine, bone marrow, gonads and lymph nodes) and tumor tissues were harvested at the indicated time points and stored in RNALater (Valencia, CA) at À80 1C. Blood samples were not analyzed for vector levels because the volume taken from the animals was only sufficient to complete the blood chemistry and hematological tests.
Between 10 and 25 mg of each tissue were used for DNA isolation using the Qiagen kit (Valencia, CA) according to the manufacturer's instructions. As bone marrow samples were formalin fixed, we followed Qiagen's instructions for purification of genomic DNA (gDNA) from formalin-fixed tissues. DNA was quantified using the Nanodrop 1000 device and stored frozen at À20 1C.
RNA extraction was performed from tissue samples that had more than five copies of Ad-ISF35 DNA in 100 ng gDNA using Qiagen kit (Valencia, CA) following the manufacturer's instructions. RNA was quantified by Nanodrop 1000 and stored frozen at À80 1C. In all, 100 ng of mRNA was converted to cDNA by reverse transcriptase PCR method for further analysis by qPCR.
Quantification of Ad-ISF35 vector and ISF35 gene expression qPCR was performed using 100 ng of gDNA or cDNA per reaction. This assay was optimized to detect at least five DNA copies of ISF35 in 100 ng of gDNA or cDNA following FDA guidelines. 17 All the samples were tested in duplicate with a cycle threshold (Ct) variability that was o5% for Ad-ISF35 amplification. The following primers at a concentration of 400 nM were used for ISF35 amplification: forward, 5 0 -CCTCTGGCTGAAGCCCAG-3 0 ; reverse, 5 0 -CTCCCAAGTGAATGGATTGT-3 0 . The TaqMan MGB-FAM probe 5 0 -TTACTCAAGGCGGCAAA-3 0 was used at 250 nM. The PCR reaction was run using TaqMan qPCR Universal Master Mix w/UNG from Applied Biosystems (Foster City, CA). The qPCR program employed a denaturation step at 95 1C for 3 min. In all, 40 cycles of subsequent amplification steps were executed 95 1C for 20 s, 52 1C for 1 min and 20 s in Bio-Rad cycler iQ5 PCR machine. The expected size of the DNA fragment amplified by these primers was 100 bp. b-Actin gene was used as a positive control for DNA quality and PCR amplification. b-Actin gene amplification was conducted using the Applied Biosystems kit following the manufacturer's instructions in 7900HT Fast Real-Time PCR system. b-Actin gene amplification was accomplished using the same PCR cycles' temperature described above. To calculate the ISF35 DNA copies present in given sample of gDNA or cDNA, we followed the Applied Biosystems protocol. 18 
Clinical observations
The general health of the animals was monitored daily according to Explora BioLab's standard operating procedures. Body weight and tumor volume were measured twice per week after Ad-ISF35 injection for a total of 4 weeks. Clinical observations were conducted and recorded twice per week beginning on the day of viral administration until the necropsy. The mice were euthanized at completion of the study according to the protocol and their organs (brain, lung, heart, spleen, liver, kidney, small intestine, gonads and lymph nodes) were harvested and weighed. Blood samples were collected via cardiocentesis under isoflurane anesthesia and animals were killed immediately by cervical dislocation. Blood samples were used for hematology and serum chemistry analysis and tissues were preserved for histopathology and molecular studies.
Hematology tests
A measure of 300 ml of blood was placed in a microcentrifuge tube containing EDTA and stored until tested. Hematology parameters analyzed included: white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell differential, smear evaluation by technologist for white and red blood cell morphology and parasite screen, pathologist review of abnormal cells and absolute reticulocyte count.
Serum chemistry tests
A measure of 500 ml of blood was placed in serum separator tubes, allowed to clot at room temperature for 30 --60 min and centrifuged at 10 000 g for 2 min. Serum was transferred into a fresh tube and placed on ice before being tested. Serum chemistry parameters analyses were: alkaline phosphatase, chloride, creatinine, glucose, phosphorous, alanine aminotransferase (SGPT-ALT), albumin, aspartate aminotransferase (SGOT-AST), total bilirubin, blood urea nitrogen, calcium, cholesterol, potassium, total protein and sodium.
Pathology analysis
Comprehensive necropsy was performed for each animal. Gross pathological observations were recorded. Selected organs (brain, lungs, heart, spleen, liver, kidney, small intestine, ovary or testis and lymph nodes) were harvested, weighted and macroscopic evaluations were performed and recorded.
Detection of Ad-Nabs assay
Mice were immunized subcutaneously with Ad-5 or Ad-ISF35 (3 Â 10 10 vp) once weekly for 3 weeks. Serum samples were collected 2 weeks after the last immunization. Neutralizing activity of the antibodies in the serum was assessed by pre-incubation of Ad-ISF35 (100 instruction for use) with serum samples at different dilutions (10 À2 --10 À6 ) for 10 min at 37 1C. Then, the vector was added to 2 Â 10 5 HeLa cells seeded in 96-well plates in a final volume of 100 ml. After 48 h of incubation, cells were harvested using trypsin-free solution and stained with anti-mCD154 antibody to detect ISF35 protein expression. Fluorescence data were acquired using FACSCalibur (BD Biosciences, San Diego, CA) and analyzed using Flow Jo v6.4.7 (Tree Star, Ashland, OR).
Statistical analysis
This study was conducted taking into account the minimum number of mice that allowed us to find a 10% difference between the treated and control groups with an a ¼ 0.05 and power ¼ 90% following the FDA guidelines. 17 Group mean, standard deviation calculation and toxicology data were analyzed using one-way analysis of variance and the significance of intergroup differences was analyzed using Bonferroni's 't'-test. The statistical analysis was performed using Prism Version 4.03, GraphPad Software (San Diego, CA).
RESULTS
Ad-ISF35 injections induced A20 tumor growth inhibition
Anti-tumor activity of Ad-ISF35 was analyzed in A20 tumor bearing mice receiving repeat administration of Ad-ISF35. Mice (female and male) were injected intratumorally with vehicle or Ad-ISF35 using 3 Â 
Clinical observations
Mice were evaluated daily after A20 tumor development and Ad-ISF35 administration to identify toxicities and/or dead animals (n ¼ 100). The rate of scheduled termination in this study was 95%. Five animals were found dead before the scheduled date of being killed. They showed massive tumor burden and multiple organ metastases. There were no differences in death frequency in the mice treated with vehicle control or Ad-ISF35. No additional micropathological review, vector biodistribution or transgene expression were performed for these animals due to tissue decomposition.
Mice that received Ad-ISF35 administration developed a hematoma and ecchymosis on the tumors 2 --4 days after the first Ad-ISF35 administration (Figure 1c) . We noticed that while the tumor size decreased, the initial hematoma turned into a dry scab. In addition, these mice developed mild-to-moderate rough coat on day 15. The frequency of rough coat was associated with the Ad-ISF35 injected dose, this was present in 50% of mice that received 3 Â 10 9 vp and 100% of mice that received 3 Â 10 10 vp (data not shown). The control group that received vehicle only started to develop rapid tumor progression and necrosis on day 9 and did not form a hematoma-like bruise or dry scab tissue.
Effect of Ad-ISF35 on body and organ weights Body and organ weights were measured in all animals on the scheduled termination date. In general, there were no significant changes in mean body weights of animals treated with single or repeat administration on either dose of Ad-ISF35. The lymph node weight was increased in the male and female groups that received single administration, but not in the group of mice treated with repeat administration of Ad-ISF35 compared with the vehicle group. The spleen weight was increased only in female mice receiving single administration with 3 Â 10 10 vp Ad-ISF35 compared with the vehicle group. Weight of reproductive organs was decreased in both male and female groups receiving vehicle compared with the mice treated with either dose of Ad-ISF35 (Supplementary Figure S1) . The changes in organ weights were transient and did not persist for longer than 15 days after injection.
Effect of Ad-ISF35 on serum chemistry and hematology parameters All of the laboratory parameters were found within normal range. However, there were statistical differences in neutrophils and platelet counts between the groups receiving single Ad-ISF35 administration and vehicle. Specifically, we observed increased neutrophil counts in females that received Ad-ISF35 with no difference among the dose groups, and increase in platelet counts in males receiving 3 Â 10 10 Ad-ISF35 (Supplementary Figure S2) .
Histopathological findings A comprehensive necropsy was conducted in all animals on the date of scheduled termination. There was no evidence of direct toxicity with Ad-ISF35 administration irrespective of the dose used. Brain, lungs, kidney, small intestine and ovary/testis tumor appeared to be normal. Histopathology analysis was only performed in mice treated with repeat administration of Ad-ISF35 and vehicle control ( Table 2 ). Mice treated with Ad-ISF35 showed hepatic extramedullary hematopoiesis and appeared to have reduction in liver metastasis compared with vehicle control group, but this was not statistically significant. Only Ad-ISF35-treated mice developed lymphoid hyperplasia and extramedullary hematopoiesis in the lymph nodes (P ¼ 0.0057). We observed extramedullary hematopoiesis and follicular hyperplasia in the spleen of mice injected with vehicle as well as Ad-ISF35. However, the presence of severe extramedullary hematopoiesis with follicular hyperplasia was more frequent in mice that received 3 Â 10 10 vp Ad-ISF35 (P ¼ 0.02). Epicardial calcification was found with similar frequency in mice that received Ad-ISF35 or vehicle. This is considered a nonspecific lesion commonly found in inbred mice. 19 Overall, histopathology analysis of internal organs showed no evidence of direct toxic effects of Ad-ISF35 with any of the two doses used.
Ad-ISF35 DNA vector biodistribution after intratumoral administration Vector biodistribution was analyzed at different time points (2, 6, 24, 48 and 120 h) after single administration of Ad-ISF35 at a fixed dose of 3 Â 10 10 vp. At 2 h after administration of Ad-ISF35, the vector was found in all 10 organs tested (copy number range 1 Â 10 1 to 1 Â 10 6 copies per 100 ng gDNA). Tumor tissues showed at least 1000 times higher copy number (B1 Â 10 9 copies/100 ng gDNA) compared with the organs evaluated. We observed a rapid clearance of Ad-ISF35 vector from the organs tested during the first 24 h, with no evidence of persistence 5 days after intratumoral administration (Figure 2 ). In contrast, vector presence in tumor samples was still detectable at 5 days after administration with an Ad-ISF35 copy number of B1 Â 10 4 copies per 100 ng of gDNA. We tested whether repeat administration of Ad-ISF35 (once every week for 3 weeks) impacts biodistribution and persistence of Ad-ISF35 vector. To assess this, we measured vector copy numbers in the injected tumor (using two doses 3 Â 10 9 or 3 Â 10 10 vp) and peripheral organs 5 days after the third intratumoral administration of Ad-ISF35 and compared these values with those from mice that received only a single injection (Figure 3a and b) .
In general, we observed that injected tumors had higher copy numbers of Ad-ISF35 vector compared with peripheral organs. Very low copy numbers, close to the threshold of detection, were detected in lymph nodes from two mice treated with one injection (one in each dose group), in two spleen and two kidney samples from mice receiving multiple injections with 3 Â 10 10 vp of Ad-ISF35. Importantly, none of the mice evaluated showed transduction of liver cells with Ad-ISF35, this is reassuring as viral hepatitis with Ad vector can be the source of major clinical complications following Ad -based gene therapy. We also detected 
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Ad-ISF35 in the testis of one mouse receiving one 3 Â 10 10 vp Ad-ISF35 injection (Figure 3a) and one mouse receiving vehicle (Figure 3c ). These findings may be due to tissue contamination rather than true presence of Ad-ISF35 vector in the testicular tissue as it was also observed in the vehicle-treated mouse.
In tumor tissues, there was no significant statistical difference in Ad-ISF35 copy number in mice receiving single or repeat administration of Ad-ISF35 or the dose injected. Ad-ISF35 presence in tumors from mice receiving repeat administration (26%) was lower compared with mice receiving single administration (50%).
We examined Ad-ISF35 vector presence 25 days after the third injection with 3 Â 10 10 vp of Ad-ISF35 in a follow-up group of nine mice. Ad-ISF35 was detected in tumor tissue in one of seven samples (the other two mice had complete regression and no tumor tissue was found) with a copy number of 1.7 Â 10 3 copies per 100 ng gDNA. Very low copy numbers (5 --12 copies per 100 ng gDNA), close to the limit of detection (5 copies per 100 ng gDNA), were also detected in two spleen samples (Figure 3d ).
Evaluation of ISF35 mRNA expression in tissues after intratumoral injection We evaluated the mRNA expression of ISF35 (CD40 chimeric gene encoded by Ad-ISF35) in all positive samples for Ad-ISF35 DNA vector on day 5. Overall, 53% of samples positive for Ad-ISF35 DNA also showed ISF35 mRNA expression. ISF35 mRNA was found more frequently in mice receiving single (50%) vs repeat administration (17%). One kidney sample from a mouse receiving three injections of 3 Â 10 10 vp of Ad-ISF35 was positive for ISF35 mRNA. In the follow-up group, we observed ISF35 mRNA expression in the tumor tissue, but not in spleen samples (Table 3) .
Analysis of pre-existing Ad Nabs in anti-tumor activity induced by Ad-ISF35 We investigated the effect of pre-existing Nabs against Ad-5 or Ad-ISF35 on vector biodistribution and anti-tumor activity. Mice were immunized by intraperitoneal injection of Ad-5 or Ad-ISF35 once every week for 3 weeks. Serum samples were evaluated for the presence of Nabs that could block Ad-ISF35 transduction of HeLa cells. All immunized mice showed Nabs titers higher than 1:10 000. There was no statistical difference between the antibody titers induced by Ad-5 or Ad-ISF35 or in their ability to neutralize Ad-ISF35 transduction of HeLa cells (Figure 4a) . A20 cells were then implanted in the right flank of pre-immunized mice, and when tumors were 4125 mm 3 , the mice received single Ad-ISF35 administration with 3 Â 10 10 vp. Mice were killed 2 h after Ad-ISF35 administration and vector presence in tumor tissues and organs was assessed by qPCR. Pre-existing antibodies against Ad-5 or Ad-ISF35 reduced vector distribution to most of the organs with a significant decrease of vector copy number in the injected tumor (Figure 4b) .
We also measured in vivo the ability of Nabs against Ad-5 or Ad-ISF35 to block the activity of repeat intratumoral administration of Ad-ISF35. Our results showed that the anti-tumor activity of Ad-ISF35 was not abrogated by Nabs against Ad-5. On the contrary, Nabs against Ad-ISF35 completely blocked the anti-tumor activity of Ad-ISF35 (Figure 4c ).
DISCUSSION
Ad-ISF35 is a replication-defective Ad encoding a genetically engineered, membrane-stabilized CD154 homolog (ISF35). CLL patients treated with autologous leukemic cells expressing ISF35 have shown clinical objective responses such as decrease in leukemia cell counts and decrease in the size of lymph nodes and spleen. 15, 16 However, this procedure requires leukapheresis of tumor cells, which are not always available and ex vivo manipulation of the cells at specialized facilities. Several groups have used intratumoral administration of recombinant adenoviral vectors as a promising strategy for effective local gene transfer, 20 --24 avoiding the hepatotoxicity and anaphylactic reactions induced by systemic intravenous administration. 25 --29 Therefore, we evaluated the administration of Ad-ISF35 by intratumoral direct injection, which allows us to expand potentially the clinical application of Ad-ISF35 in lymphomas and solid tumors.
We previously conducted preclinical studies in A20 tumor bearing mice in which intratumoral administration of Ad-ISF35, but not control vector or vehicle, resulted in tumor regression, systemic immune response and induction of protective immunity against subsequent challenge with A20 tumor cells (unpublished data). These encouraging results prompted us to perform a phase I clinical study in patients with CLL (paper submitted for publication). Patients in this trial received a single Ad-ISF35 administration directly into pathologically enlarged lymph nodes. We observed significant reductions in blood leukemia cell counts and a median reduction of 53% in the size of lymph nodes and/or spleen. Two out of 15 patients achieved a partial response based on the NCI-96 and iwCLL-2008 response criteria, 30, 31 and the response was durable (Z4 months) in nine patients. Although there was no evidence of Ad-ISF35 dissemination beyond the injected lymph node, the majority of peripheral blood leukemia cells expressed death receptors, pro-apoptotic proteins and immune co-stimulatory molecules. These phenotypic changes are similar to 'bystander' CLL cells co-cultured with Ad-ISF35 transduced cells in vitro (data not shown).
On the basis of these encouraging results, we hypothesize that repeat Ad-ISF35 administration could render a higher response rate. In preparation for these clinical trials in humans, we conducted experiments to study the safety, vector biodistribution, persistence, gene expression and effect of pre-existing antibodies against Ad after multiple Ad-ISF35 injections in A20 bearing BALB/ c mice.
In general, all mice appeared to be healthy throughout the observation period (40 days). No major abnormalities were found by clinical observation, comprehensive necropsy, gross pathological observations, major organ weight, hematology, serum chemistry and histopathology analysis. It is interesting that mice injected with Ad-ISF35 had increases in platelet and neutrophil counts, which were also observed in our phase I intranodal study. Typically Ad-based therapies have been associated with thrombocytopenia. 32 --35 This observation suggests that Ad-ISF35 probably activates CD40 expressed on the platelet surface inducing platelet detachment from endothelial vessels or through other indirect mechanisms that can promote megakaryocyte maturation and/or platelet increase. 36, 37 Moreover, the fact that the platelet elevation has been consistently observed in mice and humans receiving Ad-ISF35 suggest that this laboratory parameter can be used as a surrogate marker for Ad-ISF35 systemic activity. The observed neutrophilia observed could be due to a direct interaction between Ad and neutrophils as shown before, 38 or due to the release of cytokines after Ad administration.
In this mouse model, we show that repeat intratumoral administration of Ad-ISF35 induced significant tumor regression in the majority of mice regardless of the dose used (3 --30 Â 10 9 vp). One Ad-ISF35 injection as well as vehicle injection showed no anti-tumoral effect. Moreover, the activity of Ad-ISF35 was not due to the nonspecific effect from the Ad vector alone, as mice injected with Ad-5 (empty vector control) did not show tumor regression. After intratumoral injection, Ad-ISF35 DNA was found in all organs tested at 2 h. The vector copy number decreased rapidly after 6 h and by 24 h it was only detectable in tumor samples. This shows that Ad-ISF35 biodistribution after intratumoral injection in this animal model was broad with rapid vector clearance and lack of evidence for persistence or Abbreviations: Ad, adenovirus; NS, no sample was available because tumor tissue was very small (due to tumor regression) and enough only for DNA extraction.
Ad-ISF35 is safe and induces tumor regression J Melo-Cardenas et al replication. Very importantly, Ad-ISF35 did not accumulate or infect cells in the liver or produce elevation in serum transaminases. These results seem to disagree with reports in the scientific literature that show hepatic dysfunction and Ad vector accumulation/persistence in the liver for more than 24 h after intratumoral Ad vector injection. 23, 39, 40 The method of vector detection (qPCR vs luciferase chemoluminescence) or particular characteristics of the Ad-ISF35 vector may have influenced these results. Additional factors such as the tumor size, frequency, dose, volume of injections and vector degradation by the liver may influence organ distribution and persistence as well. 41 Using a high-sensitivity qPCR assay, we found Ad-ISF35 DNA in the brain of mice immediately after intratumoral administration. The vector clearance from brain tissue was rapid and occurred within the first 6 h after Ad-ISF35 injection, suggesting that the source of the vector was circulating blood and not direct transduction of brain cells. In addition, analysis of brain tissues did not show histological abnormalities to suggest viral encephalitis or differences between Ad-ISF35-injected and vehicle-treated groups. Published reports typically had performed the assessment of vector biodistribution in the brain at 24 h or later time points and that is probably one of the reasons why they do not report similar findings. 23, 39 The dose of Ad-ISF35 did not have a major effect on vector biodistribution. We did not observe differences in organs from animals injected with either one of the doses used in our study (3 Â 10 9 or 3 Â 10 10 vp). However, we observed a higher copy number in tumor tissues injected once with 3 Â 10 10 vp dose compared with the 3 Â 10 9 vp dose, but the difference was not statistically significant. Repeat intratumoral administration of Ad-ISF35 had a lower frequency and copy number of positive tumors for Ad-ISF35 DNA and mRNA compared with single injected tumors. This observation might be related to the presence of Nabs against Ad-ISF35 or the decrease in the size of the target tumor injected, as mice experienced tumor regression with each Ad-ISF35 injection.
Histopathology analysis of mice treated with 3 Â 10 10 vp Ad-ISF35 showed severe extramedullary hematopoiesis and follicular hyperplasia in the spleen and lymphoid hyperplasia with extramedullary hematopoiesis in lymph nodes. This could be related to an immune response induced by the vector and/or the transgene (ISF35). Similar findings of severe splenic extramedullary hematopoiesis have been reported in mice receiving CpG oligodeoxynucleotides and it is believed these effects correspond to an immune/inflammatory-mediated process. 42 The presence of pre-existing anti-Ad antibody titers could play a major role in the in vivo vector delivery and activity when injected into human tissues. Ad is a common virus that causes cold and the large majority of the population has anti-Ad antibodies with variable neutralizing activity. 43 --45 Therefore, we conducted experiments to study the role of neutralizing anti-Ad antibodies on the activity of Ad-ISF35 in vivo. The presence of pre-existing Nabs against Ad-5 did not abrogate the anti-tumor effect of Ad-ISF35 injections. The reason for this is not entirely clear. However, other reports have shown that antibodies against Ad-5 do not neutralize the activity of recombinant Ad vectors. 46 It is possible that the presence of Nabs may contribute to dendritic cell activation, increasing anti-tumoral activity as shown previously. 47 On the other hand, it has been reported that anti-tumor activity using CD154 can be achieved with only 0.3% of cells expressing CD154. 48 All these factors could explain why intratumoral administration of Ad-ISF35 was still effective despite the presence of anti-Ad vector serotype 5 Nabs. The observation that Nabs against Ad-ISF35 abrogated tumor response could be due to production of anti-ISF35 antibodies that interfered with its activity. Because ISF35 is an engineered human --mouse chimeric CD154 homolog in which the majority of the sequence is human (unpublished data; Memgen LLC), and the sites recognized by Nabs in previous clinical trials were removed, it is expected that this protein could be immunogenic in mice but much less, if at all, in humans. To investigate this issue, we plan to evaluate the production of anti-ISF35 antibodies in human patients enrolled in phase II clinical trials using Ad-ISF35. Taken together, these results suggest that naturally occurring antiAd antibodies may not reduce the activity of Ad-ISF35 when used in humans.
In conclusion, Ad-ISF35 intratumoral administration induced anti-tumoral activity with eradication of A20 lymphoma in more than 80% of mice, showed a safe administration profile and did not induce signs of toxicity in A20 bearing mice. Ad-ISF35 vector was rapidly cleared with no evidence of accumulation or persistence in this animal model. Ad-ISF35 anti-tumor activity was preserved even when Nabs against wild-type Ad (Ad-5) were present. The safe biodistribution profile, lack of vector persistence and activity of Ad-ISF35 provides the rationale to continue the clinical development of this vector with the aim to treat patients with B-cell malignancies and CD40 expressing solid tumors.
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